Coal tar 10% / Salicylic acid 2% / Sulfur 2% in Generic Unguentum M cream
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 1 · 1982–2026
Showing the 50 most relevant studies, sorted by most relevant.
X. Querol, X. Zhuang, O. Font, et al.
International Journal of Coal Geology, 2011
Jacobi A, Mayer A, Augustin M
2015
IntroductionPsoriasis is a common chronic disease with significant impairment in quality of life. As there is no cure, it often requires lifelong disease control to minimize the development of skin lesions and to relieve symptoms. The aim of this publication is to systematically review the role of currently used emollients and keratolytics in the treatment of psoriasis.MethodsA systematic literature search was conducted in Medline via PubMed regarding reviews, meta-analyses, and trials published from January 1983 to December 2013 dealing with topical administration of emollients and keratolytics in patients with psoriasis. A subsequent search in EMBASE regarding clinical trials published from 1983 to 2013 was performed to complement the findings.ResultsA total of 60 publications met the inclusion criteria for full-text evaluation. While current reviews, meta-analyses, and guidelines state that adjuvant therapy with emollients and keratolytics should be an obligatory part in the therapy of psoriasis to facilitate descaling and/or penetration enhancement, comprehensive trials on these agents are missing, with the exception of combination products containing salicylic acid and corticosteroids. In the mentioned trials, addition of salicylic acid was beneficial in inducing a more rapid onset of action as well as a reduction of severity parameters and the area affected. However, its use has substantial limitations in young children, in patients with renal/hepatic impairment, with widespread psoriasis, those undergoing phototherapy, or those concomitantly treated with calcipotriene/systemic salicylates.ConclusionIn view of these shortcomings, there is a need for well-designed studies on suitable keratolytic alternatives to salicylic acid offering an indisputable positive benefit-risk ratio.
Abstract licence: CC BY-NC
Yan Jing Chen, Tang Jie, Lin Wang, et al.
Journal of Cosmetic Dermatology, 2025
- Dermatologic Agents
- Skin Diseases
- Sulfur
Syaiful Arif, Gunawarman, S. Bakhri, et al.
Journal of Physics: Conference Series, 2026
The demand for high-performance graphite continues to increase, particularly for applications such as batteries, metallurgy, and thermal management. This has driven the development of more energy-efficient synthesis technologies. This literature review discusses recent developments in pyrolysis-based catalytic graphitization methods utilizing two widely available aromatic carbon precursors: petroleum coke and coal tar pitch. The main focus includes the catalyst type used (Fe, Ni, Co, Mo, alkali/alkaline earth, B, Si), the application method (salt impregnation, mechanical mixing, or in-situ mineralization), and process configurations such as pitch pre-oxidation, heating rate, N2/Ar inert atmosphere, process temperature (800–1600°C), and residence time. Structural and performance parameters of the graphite products studied include d002 value, crystalline dimension (Lc/La), Raman ID/IG ratio, electrical conductivity, material strength, and final product yield. The study shows that transition metals are effective in lowering the graphitization temperature compared to uncatalyzed methods. The process involves a dissolution and precipitation mechanism through the formation of metastable carbides, which can reduce the d002 value to 0.335–0.339 nm while increasing the graphitic domains. Meanwhile, alkali and alkaline earth cations accelerate the reordering of aromatic rings but can trigger gasification, which reduces product yield. Boron also plays a role in increasing the regularity of the crystal lattice and reducing structural defects. Intrinsic characteristics of the precursor, such as sulfur, nitrogen, and ash content in petroleum coke, as well as the formation of mesophases and QI fractions in pitch, can affect the effectiveness of the catalyst or even inhibit its activity. Therefore, the need for pretreatment and purification is crucial.This approach faces several key challenges, such as balancing energy efficiency with final product purity. Acid protection to remove residual metals, technological scalability issues, and safety aspects are also important concerns. Optimal parameters identified include the use of 3–7 wt% catalyst, gradual heating, pre-oxidation of pitch before pyrolysis, and a process duration of 1–3 hours, which have shown promising results. However, further research is needed to address aspects such as multiscale mechanistic modeling, control of feedstock heterogeneity, continuous reactor design, catalyst recycling, and product lifecycle sustainability analysis. Overall, this catalytic graphitization method shows great potential for producing high-performance graphite at lower process temperatures. This technology has important implications for the manufacture of battery anodes, conductive composite materials, and refractories in large-scale, sustainability-oriented industries.
Abstract licence: CC BY
S. Khandpur, K. Sahni
Indian Journal of Dermatology, 2014
Kravchenko S.A., Starovoit A.G., Turkina O.V., et al.
Journal of Coal Chemistry, 2022
Nuraly S. Akimbekov, Ilya Digel, Куаныш Тастамбек, et al.
Biology, 2022
Lerato Sekhohola‐Dlamini, Sohail Khan, Bobo Wang, et al.
Biodegradation, 2025
- Bacteria
- Coal
- Fungi
H. Franklin, W. Peters, J. Howard
1982
Yuhan Xia, Arno R. De Klerk
Processes, 2025
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.